<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859973</url>
  </required_header>
  <id_info>
    <org_study_id>1346-0038</org_study_id>
    <secondary_id>2018-002740-82</secondary_id>
    <nct_id>NCT03859973</nct_id>
  </id_info>
  <brief_title>This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia</brief_title>
  <official_title>A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of BI 425809 Once Daily With Adjunctive Computerized Cognitive Training Over 12 Week Treatment Period in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this Phase II exploratory trial is to provide Proof of Concept (PoC)
      data to assess the effect on cognition of oral once daily administration of BI 425809 given
      for 12 weeks in patients with schizophrenia on stable antipsychotic treatment and adjunctive
      Computerized Cognitive Training (CCT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">June 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 7, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in neurocognitive function as measured by the neurocognitive composite score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cognitive function as measured by the overall MCCB composite score (including social cognition)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the effect of cognitive deficit on day-to-day functioning as measured by SCoRS total score</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Schizophrenia Cognition Rating Scale (SCoRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Positive and Negative Syndrome Scale (PANSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with (S)AEs</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>BI 425809</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active drug treatment arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo drug arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809</intervention_name>
    <description>Tablet</description>
    <arm_group_label>BI 425809</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated written informed consent in accordance with ICH Harmonized Tripartite
             Guideline for Good Clinical Practice (ICH-GCP) and local legislation prior to
             admission to the trial.

          -  Male or female patients who are 18-50 years (inclusive) of age at time of consent.

          -  Established schizophrenia (as per DSM-5) with the following clinical features:

               -  Outpatient, with no hospitalization for worsening of schizophrenia within 3
                  months prior to randomization

               -  Psychiatrically stable without symptom exacerbation within 3 months prior to
                  randomization

               -  PANSS score ≤ 5 on positive items P1, P3-P7 and ≤ 4 on positive item P2 at Visit
                  1, and confirmed at Visit 2

          -  Patients must be on stable antipsychotic treatment, and current antipsychotic and
             concomitant psychotropic medications must meet the criteria below:

               -  Patients may take up to 2 antipsychotics (typical and/or atypical), except for
                  clozapine

               -  Patients must be stable on current antipsychotics and concomitant psychotropic
                  medications (e.g. anticholinergics, antiepileptics, lithium and allowed
                  antidepressants) for at least 3 months prior to randomization and be on current
                  dose for at least 30 days prior to randomization ---Patients on Long-Acting
                  Injectable (LAI) antipsychotics should be on the same medication and dose for at
                  least 3 months prior to randomization

          -  Women of childbearing potential (WOCBP)2 must be ready and able to use highly
             effective methods of birth control per Non-Clinical Safety Studies for the Conduct of
             Human Clinical Trials and Marketing Authorization for Pharmaceuticals (ICH M3 (R2))
             that result in a low failure rate of less than 1% per year when used consistently and
             correctly. Such methods should be used throughout the trial, and for a period of at
             least 35 days after last trial drug intake, and the patient must agree to periodic
             pregnancy testing during participation in the trial.

          -  Patients must demonstrate their ability to properly use the computerized cognitive
             training (CCT) device and program, as well as be compliant with CCT run-in (defined as
             completing at least 2 hours per week for two weeks, totalling 4 hours CCT, during the
             screening period).

          -  Patients must be able to comply with all protocol procedures including the at-home CCT
             exercises, in the investigator's opinion.

          -  Patients must have a study partner who will preferably be consistent throughout the
             study. It is recommended that the study partner should interact (in-person or
             telephone) with the subject at least 2 times a week.

        Exclusion Criteria:

          -  Patients who have a categorical diagnosis of another current major psychiatric
             disorder on the Mini-International Neuropsychiatric Interview (M.I.N.I.).

          -  Diseases of the central nervous system (CNS) that may impact the assessment of the
             cognitive tests as per investigator's opinion.

          -  A movement disorder due to antipsychotic treatment not currently controlled with anti-
             EPS treatment or another movement disorder (e.g. Parkinson´s disease).

          -  Patients with a history of participating in any formal cognitive remediation program
             for 10 or more training sessions.

          -  Patients who were treated with any of the following medications within the last 6
             months prior to randomization:

               -  Bitopertin, BI 409306, encenicline or other investigational drug testing effects
                  on cognition in schizophrenia

               -  Clozapine (atypical antipsychotic medication)

               -  Sarcosine, cycloserine, serine and glycine

               -  Stimulants (e.g. methylphenidate, dextroamphetamine, modafinil)

               -  Tricyclic antidepressants

          -  Patients receiving any other investigational drug (other than a potential cognitive
             enhancing drug) within 30 days or 6 half-lives (whichever is longer) prior to
             randomization. For investigational LAI antipsychotics, the last injection must be at
             least 3 months or two administration cycles (i.e. 6 months if administration is every
             3 months) prior to randomization, whichever is longer.

          -  Patients who have participated in a clinical trial with repeated assessments (i.e. a
             single assessment is not exclusionary) with the MATRICS Consensus Cognitive Battery
             (MCCB) within the last 6 months prior to randomization.

          -  Patients who required a change in ongoing benzodiazepine or sleep medication dose or
             regimen within the last 30 days prior to randomization.

          -  Use of systemic steroids within 30 days prior to randomization.

          -  Patients taking strong or moderate CYP3A4 inhibitors or inducers within the last 30
             days prior to randomization. A list of strong or moderate CYP3A4 inhibitors and
             inducers will be provided in the ISF.

          -  Patients who must or wish to continue the intake of restricted medications or herbal
             remedies

          -  Patients who received treatment with medical devices (e.g. TMS, neurofeedback) for any
             psychiatric condition within the last 3 months prior to randomization.

          -  Patients who have received electroconvulsive therapy (ECT) within 6 months prior to
             randomization or repeated courses of ECT within the past 2 years.

          -  Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt,
             aborted attempt, or preparatory acts or behavior) prior to randomization.

          -  Any suicidal ideation of type 4 or 5 in the C-SSRS in the past 3 months (i.e. active
             suicidal thought with intent but without specific plan, or active suicidal thought
             with plan and intent) prior to randomization.

          -  Any of the following, in the judgment of the investigator:

               -  Clinically significant finding of the physical examination, vital signs
                  (including blood pressure (BP) and pulse rate (PR)), ECG or laboratory value (as
                  measured by the central laboratory) that would jeopardize the patient's safety
                  while participating in the trial or their capability to participate in the trial.

               -  Symptomatic/unstable/uncontrolled or clinically relevant concomitant disease or
                  any other clinical condition that would jeopardize the patient's safety while
                  participating in the trial or capability to participate in the trial.

               -  Significant or unstable physical condition that may require change in medication
                  or hospitalization that would impact cognitive function, or planned elective
                  surgery requiring general anesthesia during the study period.

               -  Patients for which cognitive or other impairment (including severe hearing
                  impairment) or symptom severity compromises the ability to perform the CCT or
                  assessments related to cognitive outcome measures.

          -  Severe renal impairment defined as an eGFR &lt; 30mL/min/1.73m² in the Visit 1 central
             lab report.

          -  Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT),
             or alkaline phosphatase above 3 times upper limit of normal as determined in the Visit
             1 central lab report.

          -  Known history of HIV infection based on review of medical history and/or a positive
             result for ongoing Hepatitis B or C infection on the Visit 1 central lab report.

          -  Any documented active or suspected malignancy or history of malignancy within 5 years
             prior to screening, except appropriately treated basal cell carcinoma of the skin,
             squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix.

          -  Hb less than 120 g/L (12g/dL) in men or 115 g/L (11.5g/dL) in women at Visit 1.

          -  History of hemoglobinopathy such as thalassemia major or sickle-cell anemia.

          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial.

          -  Significant history of drug abuse disorder within the last 6 months prior to informed
             consent (including alcohol, as defined in DSM-5-substance use disorder or in the
             opinion of the investigator), or a positive urine drug screen at Visit 1. Note:
             Patients testing positive for cannabis on urine drug screen at Visit 1 may be
             re-tested once if there is a reasonable explanation and expectation that the patient
             will not test positive again on re-test, and at the discretion of the investigator.

          -  Patients who are not fluent in the language of the batteries/questionnaires which will
             be used in the country.

          -  Patient who did not make an effortful attempt to complete the cognition battery at
             Visit 1 in the clinical judgement of the investigator.

          -  Patients that previously received treatment in any study with BI 425809.

          -  Patients with an allergy to BI 425809 and/or any of the excipients (including lactose)
             or placebo ingredients. A list of BI 425809 and placebo ingredients will be provided
             in the ISF.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atria Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prasad Padala</last_name>
      <phone>+001 (608) 848-8900</phone>
      <email>drpadala@atriaresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Woodland Research Northwest</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Billingsley</last_name>
      <phone>+001 (479) 927-3000</phone>
      <email>drbillingsley@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC (CNS)</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Walling</last_name>
      <phone>+001 (714) 799-7799</phone>
      <email>davidwalling@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synergy San Diego</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Bari</last_name>
      <phone>+001 (619) 327-0155</phone>
      <email>bari@synergysandiego.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute, LLC</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Volk</last_name>
      <phone>+001 (909) 445-8465</phone>
      <email>svolk@catalinari.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Research Partners, LLC</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinna Gamez</last_name>
      <phone>+001 (877) 602-5777</phone>
      <email>corinnagamez@pacifictrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NRC Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Chueh</last_name>
      <phone>+001 (714) 335-3015</phone>
      <email>dchueh@nrcresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asclepes Research Centers</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Sharma</last_name>
      <phone>+001 (310) 208-7144</phone>
      <email>Asharma@asclepes.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNRI - Los Angeles</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>90660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Manning</last_name>
      <phone>+001 (562) 928-8601</phone>
      <email>raymond.manning@cnrilallc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNRI-San Diego, LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Benbow</last_name>
      <phone>+001 (619) 481-5252</phone>
      <email>Christopher.benbow@cnrisandiego.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC (CNS)</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lara Shirikjian</last_name>
      <phone>+001 (310) 523-4200</phone>
      <email>larashirikjian@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilio Mantero-Atienza</last_name>
      <phone>+001 (305) 392-0279</phone>
      <email>emantero@pcrinstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Apalachee Center</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Jerome Golden Center for Behavioral Health</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Synexus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Davis</last_name>
      <phone>+001 (404) 255-6005</phone>
      <email>Bethany.Davis@GlobalAES.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uptown Research Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Sonnenberg</last_name>
      <phone>+001 (773) 989-8313 x118</phone>
      <email>jsonnenberg@uptownresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lake Charles Clinical Trials LLC</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70629</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kashinath Yadalam</last_name>
      <phone>+001 (337) 564-6405</phone>
      <email>yadalamk@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cherry Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Achtyes</last_name>
      <phone>+001 (616) 965-8200</phone>
      <email>ericachtyes@cherryhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aggy Vallanat</last_name>
      <phone>+001 (718) 969-3005</phone>
      <email>aggy.vallanat@synexus-us.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otto Dueno</last_name>
      <phone>+001 (937) 424-1050</phone>
      <email>odueno@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Dallas, LP</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research, LLC</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Bartley</last_name>
      <phone>+001 (214) 396-4844</phone>
      <email>sbartley@pillarhc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Aqeel Hashmi, MD, PA</name>
      <address>
        <city>Richmond</city>
        <state>Texas</state>
        <zip>77407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arifulla Khan</last_name>
      <phone>+001 (425) 453-0404</phone>
      <email>akhan@nwcrc.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>University of Sydney</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health (CAMH)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4J 1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>HOP Bohars</name>
      <address>
        <city>Bohars</city>
        <zip>29820</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>CTR Esquirol</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perrine Brazo</last_name>
      <phone>+33 (0)2 31 06 50 18</phone>
      <email>brazo-p@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Dijon-Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoît Trojak</last_name>
      <phone>+33 (0)3 80 29 37 69</phone>
      <email>benoit.trojak@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP la Colombière</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme Attal</last_name>
      <phone>+33 (0)4 67 33 97 02</phone>
      <email>j-attal@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Saint-Jacques</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Chirio-Espitalier</last_name>
      <phone>+33 (0)2 40 84 63 96</phone>
      <email>marion.chirioespitalier@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Giordana</last_name>
      <phone>+33 (0)4 92 03 77 77</phone>
      <email>giordana.b@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GHU Paris Psychiatrie et Neurosciences</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>HOP Nord</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Fakra</last_name>
      <phone>+33 (0)4 77 82 88 52</phone>
      <email>eric.fakra@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital, Takapuna</name>
      <address>
        <city>Takpuna Auckland</city>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wayne Miles</last_name>
      <phone>64 9 486 8900</phone>
      <email>wayne.miles@waitematadhb.govt.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holywell Hospital</name>
      <address>
        <city>Antrim</city>
        <zip>BT41 2RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>The Fritchie Centre</name>
      <address>
        <city>Cheltenham</city>
        <zip>GL53 9DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Warneford Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
Studies in products where Boehringer Ingelheim is not the license holder;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
Studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
Requestors can use the following link http:// trials.boehringer-ingelheim.com/ to:
find information in order to request access to clinical study data, for listed studies.
request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

